US-based minimally invasive medical devices maker Embolx has signed a global distribution partnership with Girlow USA to expand access to its medical technologies, including its Sniper Balloon Occlusion Microcatheter.

The Sniper is Embolx’s flagship product, intended to transform the embolic treatment procedures for various conditions.

It is designed to improve the delivery of embolic agents to treat different types of cancer and benign prostatic hyperplasia (BPH) while protecting the surrounding healthy tissues.

Under the partnership, Embolx plans to use Girlow’s established distribution channels and network to make this advanced technology more easily accessible beyond the US and Europe.

The collaboration will support healthcare workers and institutions across Mexico, Central America, South America, and the Caribbean to access Embolx’s technologies.

It aligns easily with its goal of offering healthcare professionals access to the latest and advanced medical technologies.

Embolx president and CEO Michael Allen said: “We are thrilled to partner with Girlow USA, a highly respected global distributor in the medical field.

“By combining our expertise, we can make significant strides in improving patient care on a global scale.”

The Sniper Balloon Occlusion Microcatheter is said to have advanced features and precision engineering to precisely target cancerous tumours.

The medical device maker said that the device allows healthcare professionals to enhance treatment efficacy and lower complications.

It received the CE mark and 510(k) clearance from the US Food and Drug Administration (FDA) in 2018.